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BRCA1 BRCT domains function as phosphoprotein-binding modules for recognition of the phosphory-
lated protein-sequence motif pSXXF. While the motif interaction interface provides strong anchor points
for binding, protein regions outside the motif have recently been found to be important for binding
afﬁnity. In this review, we compare the available structural data for BRCA1 BRCT domains in complex
with phosphopeptides in order to gain a more complete understanding of the interaction between
phosphopeptides and BRCA1-BRCT domains.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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BRCT domains
Maintaining the integrity of genetic information is key to the
survival of cells. Eukaryotes have evolved to host sophisticated cell-
cycle-dependent regulation networks to deal with DNA damage
arising from both exogenous and endogenous sources. Dynamic
proteineprotein interactions and protein complex assemblies in, phosphoinositide 3-kinase-
ne 1; HBOC, hereditary breast
lyproline II.
Ltd. This is an open access article uthe signalling cascades mediating DNA damage response (DDR) are
often initiated by protein post-translational modiﬁcation such as
phosphorylation. Reversible interaction interfaces are created by
phosphorylation on serine/threonine residues by key DDR-
signalling-cascade regulators that include phosphoinositide 3-
kinase-related kinases (PIKKs) (ATM, ATR, DNA-PK) (Matsuoka
et al., 2007; Meek et al., 2008) and checkpoint-effector kinases
(Chk1, Chk2 and MK2) (Reinhardt and Yaffe, 2009).
Deﬁciency in DDR regulation networks caused by genemutation
could potentially lead to cell death or tumorigenesis. Mutations in
the tumour suppressor gene BRCA1 (breast cancer susceptibility
gene 1) were ﬁrst identiﬁed in patients with hereditary breast and
ovarian cancer (HBOC) (Futreal et al., 1994; Hall et al., 1990; Miki
et al., 1994). Further analysis of this 1863-amino-acid BRCA1 pro-
tein led to the identiﬁcation of the BRCT (named as BRCA1-C-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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share low sequence identities (about 14%), they have been suc-
cessfully identiﬁed in many proteins involved in RNA processing,
cell checkpoint regulation and DNA damage response and repair
(Bork et al., 1997; Callebaut and Mornon, 1997; Woods et al., 2012),
where BRCT domains mediate interactions with proteins, DNA
(Yamane and Tsuruo, 1999; Yamane et al., 2000) and poly(ADP-
ribose) (PAR) (Pleschke et al., 2000).
A typical BRCT domain comprises between 90 and 100 amino-
acid residues and folds as a globular domain with secondary
structural elements ordered as babbaba. The ﬁrst crystal structure
of a BRCT domain, that of XRCC1, deﬁned a four-stranded parallel b-
sheet surrounded by three a-helices, in which helices a1 and a3
locate on one side of the b-sheet and a2 on the other side (PDB:
1CDZ) (Zhang et al., 1998) (Fig. 1a). 23 human genes have been
identiﬁed encoding BRCT domain-containing proteins and 12 of
these contain more than one BRCT domain within the sequence
(Mesquita et al., 2010;Woods et al., 2012), as does BRCA1where the
two BRCT domains are packed tightly in tandem. One of the most
signiﬁcant properties for BRCA1 BRCT domains is their ability to
bind phosphorylated proteins containing the sequence motif
pSXXF (where p indicates phosphorylation) (Manke et al., 2003;
Rodriguez et al., 2003; Yu et al., 2003) (Fig. 1b). Potential
phospho-independent interaction has also been reported recently
for interaction of BRCA1-BRCT domains with DNA-PKcs (Davis et al.,
2014). Together with the N-terminal RING domain, C-terminal BRCT
domains are the sites of the main BRCA1 mutations found in pa-
tients with breast and ovarian cancer (Couch and Weber, 1996;
Friedman et al., 1994; Shattuck-Eidens et al., 1995). Studies of
mouse models have shown that BRCT-domain phosphoprotein
binding but not the RING-domain E3-ligase activity is required for
Brca1 tumour suppression (Shakya et al., 2011). Comprehensive
reviews of the evolution and function of BRCT domains can be
found in Leung and Glover (2011), Mesquita et al. (2010). Here, we
focus on the interface between the phosphopeptide and BRCA1
BRCT domains.2. 2D-structure comparisons of BRCA1 tandem BRCT domains
bound with phosphopeptides
The availability of protein structure data for BRCA1 tandem
BRCT domains alone and in complex with various phosphopep-
tides has enabled us to understand and compare the protein-
peptide interaction in detail. We ﬁrst describe these interactionsFig. 1. BRCT domain structures. a) Crystal structure of the second BRCT domain of XRCC1 (
green. N0 (Head) and C0 (Tail) ends are labelled. b) Crystal structure of BRCA1-BRCT tandem
2004). Bach1 phosphopeptide binds to the cleft between the two BRCT domains. The ribbon
represented by a transparent surface. Bach1 phosphopeptide is in pink.using a “2D interaction map” method, built upon the structural
interaction ﬁngerprint methodology used in the CREDO structural
interactomics database (Schreyer and Blundell, 2013) (Fig. 2). All
bound phosphopeptides identiﬁed in protein structures were
sequence aligned, with the phosphorylated Ser residue, which
mediates key H-bonds in the pSXXF motif, placed at position 0. The
side chain of the Phe at the þ3 position inserts into a deep hy-
drophobic binding pocket, forms hydrogen-bond interactions via
its mainchain atoms, and interacts with the sulphur in BRCT M1775
via a ring p interaction. Outside the pSXXF motif region, the N- and
C-terminal peptides also contribute to the interaction. The struc-
ture of Bach1 in complex with a phosphopeptide (PDB: 1T29)
(Shiozaki et al., 2004) deﬁnes an especially large interface outside
the motif. The optimized phosphopeptide in the BRCA1 BRCT-
phosphopeptide complex (PDB:1T2V) (Williams et al., 2004) has
a Tyr at position 3 in the N-terminal region, which forms hy-
drophobic and ring-atom interactions through its side chain. The
“2D interaction map” in Fig. 2 provides a clear visualization for
comparing phosphopeptide interactions with BRCT domains as
well as for deﬁning the depth of the binding pockets.3. The “two anchors” binding in pSXXF motif region
The 3D structures of BRCA1-tandem-BRCT domains show that
the two BRCT domains (BRCT1 and BRCT2) are associated in a head-
to-tail manner (Williams et al., 2001). A large hydrophobic interface
between BRCT1 and BRCT2 is created by a2 (from BRCT1) and a01
and a03 (from BRCT2), with an extra linking helix aL between the
two domains, next to the a03 of BRCT2. Using the BRCA1-Bach1
structure (PDB: 1T29) (Shiozaki et al., 2004) as an example, Bach1
phosphopeptide can be seen to bind to the cleft generated between
two tightly packed BRCT domains (Fig. 1b). The pSXXF motif in
Bach1 phosphopeptide functions as a “two-anchor” interaction
mode (also described as “two-knobs” in Shiozaki et al. (2004)))
with the BRCT domain, in which the phosphorylated Ser (position
0) and the Phe (position þ3) interact with the BRCT1 and BRCT2
individually (Fig. 2b). Comparison with a BRCT-domains-only
structure (PDB: 1JNX) (Williams et al., 2001) by structural super-
position and alignment with the BRCT1-domain structure shows
that the BRCT2 domain moves closer to BRCT1 when bound to a
phosphopeptide (Fig. 2b). A larger degree of phosphopeptide-
induced domain movement was also observed in TopBP1 BRCT 7/
8- Bach1 complex (Leung et al., 2010). This suggests thatPDB: 1CDZ) (Zhang et al., 1998). The ribbon representation of the mainchain is in dark
1 and 2 domains in complex with Bach1 phosphopeptide (PDB: 1T29) (Shiozaki et al.,
representation of BRCT domain mainchain is in slate colour and the globular structure is
Fig. 2. 2D-interaction map of phosphopeptide with BRCA1-tandem-BRCT domains. Phosphopeptides in BRCA1-bound conformations from X-ray crystal structures (PDB codes on
right hand side) were aligned by sequence (only residues in positions from 5 to þ6 are shown) and their interaction proﬁles with BRCA1 determined. Coloured bars indicate the
number of interactions of a given type formed between the peptide and BRCA1 at each residue position (numbered by position in alignment, top). Binding depth in Ångstroms,
measured by Rinaccess as the smallest spherical probe size that can ﬁt into a surface cavity (Kawabata, 2010), is shown as larger, translucent grey bars. Smaller Rinaccess values
indicate deeper binding depth of the residue into BRCA1. Structures of complexes include BRCA1 BRCT bound with Bach1 (PDB: 1T15 and 1T29) (Clapperton et al., 2004; Shiozaki
et al., 2004), motif tetrapeptides (PDB: 3K0K and 3K0H) (Campbell et al., 2010), AcetylcoA carboxylase 1 peptide (PDB:3COJ) (Shen and Tong, 2008), CtIP (PDB: 1Y98) (Varma et al.,
2005), ATRIP (PDB: 4IGK) (Liu and Ladias, 2013), optimized peptide (PDB:1T2V) (Williams et al., 2004) and BAAT1 (PDB:4IFI) (Liu and Ladias, 2013).
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domains.3.1. The ﬁrst and second “anchors”
For the ﬁrst “anchor”, the phosphate group in pS (0 position)
mediates polar interactions with evolutionarily conserved residues
S1655/G1656 in b1 and K1702 in a2 of BRCA1 (Fig. 3b Top). The
phosphate group in pS cannot be replaced by the phosphate-
mimicking residue glutamic acid for motif containing tetrapep-
tide. For example, the tetrapeptide EPTF failed to bind to BRCT
domains, whereas pSPTF can (Lokesh et al., 2007). Topbp1 tandem
BRCT domains (domain 7 and 8, PDB: 3AL3) recognises a phos-
phorylated Thr instead of Ser of Bach1 at a different site (Leung
et al., 2010). The phosphate group from pT mediates an extra
interaction with the R1280 residue in a1 of Topbp1 BRCT7 (Fig. 3b
bottom). At the equivalent a1 site, BRCA1 contains an exposed
F1662, which is consistently buried in crystal packing. For the
second “anchor” interaction, the Phe side chain at þ3 position in-
serts into a deep hydrophobic pocket in the BRCT2 domain created
by L1701, F1704, N1774, M1775 and L1839. R1699 also interacts
with the mainchain of Phe via hydrogen bonds (Fig. 3d). Missense
mutations of interaction-key residues G1656, M1775 and R1699 can
be found in breast cancer patients and cause reduced/lostphosphopeptide binding property (Cantor et al., 2001; Coquelle
et al., 2011; Manke et al., 2003; Shiozaki et al., 2004; Williams
et al., 2004; Yu et al., 2003). Both in vitro and in vivo assays have
shown that M1775R mutant failed to bind to the BRCT domains
(Clapperton et al., 2004; Williams et al., 2004). Comparing the
structures of the phosphopeptide-bound BRCT domains with BRCT
(M1775R) only has shown that this mutation causes the disruption
of hydrophobic pocket, and therefore causes the side chain of þ3
position Phe to fail to insert (Clapperton et al., 2004; Williams and
Glover, 2003; Williams et al., 2004). The M1775R mutation also
changed the residue preference at þ3 position of phosphopeptide
to acidic residues (Clapperton et al., 2004).4. The X residues in pSXXF motif
Apart from the conserved “two-anchor” interaction sites, afﬁn-
ity differences among phosphopeptides towards BRCA1 BRCT do-
mains can arise from the variation of the X residues at positions þ1
and þ2 in the pSXXF motif. Superposition of four peptides (PDBs:
1T29, 1Y98, 4IGK and 1T2V) bound to the BRCT domains shows the
variation of residues at positions þ1 and þ2 (Fig. 3c). The surface
cavity of BRCT domains in these two positions is shallower than
that for positions 0 andþ3, as shown in Fig. 2. Combining structural
information and biophysical afﬁnity measurements from peptides
Fig. 3. BRCA1-tandem-BRCT-domain interaction with phosphopeptide. a) Aligning the BRCT1 domain for structures of Bach1-phosphopeptide-bound BRCT domains (PDB: 1T29)
(Shiozaki et al., 2004) and BRCT domains alone (PDB:1JNX) (Williams et al., 2001) demonstrates the movement of the BRCT2 domain. b) 0 position phosphate group interaction with
BRCT domains from BRCA1 (PDB: 1T29) (Shiozaki et al., 2004) and Topbp1 (PDB: 3Al3) (Leung et al., 2010). c) þ1 and þ2 positions of phosphopeptide from Bach1 (PDB: 1T29)
(Shiozaki et al., 2004), CtIP (PDB: 1Y98) (Varma et al., 2005), ATRIP (PDB: 4IGK) (Liu and Ladias, 2013) and optimized peptide (PDB:1T2V) (Williams et al., 2004) when bound with
BRCA1 BRCT domains. d) þ3 Phe interaction with BRCT2 domain in Bach1 (PDB: 1T29) (Shiozaki et al., 2004). In a), b), c), and d) BRCA1 BRCT domains are in slate colour, Bach1
phosphopeptide in 1T29 is in pink, TopBP1 BRCT 7-8 BRCT domains are in green, Bach1 phosphopeptide in 3AL3 is in yellow, BRCA1-BRCT-only structure is in wheat. Polar
interaction is indicated in grey dashed lines. Residues labelled for the BRCT domain is highlighted with grey. e) Ramachandran plots (Ramachandran et al., 1963) of the phos-
phopeptides (1 to þ4 positions) in BRCT domains bound conformations. Residues are coloured by their positions in the sequence-based alignment of the pSXXF motif peptides.
Blue horizontal and vertical lines intersect at the ideal phi/psi angles of proline in a polyproline II helix.
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Fig. 4. Hydrophobic regions in BRCA1-BRCT domains bound with phosphopeptide N-terminal sequence outside the pSXXF motif. The hydrophobic regions of the BRCA1-BRCT
domains, indicated by red colour, comprise three patches, which are highlighted using dashed circular line. The interactions in Patches 1 and 2 are detailed on the right. Bach1
phosphopeptide from PDB: 1T29 (Shiozaki et al., 2004) is in pink, while the optimized peptide from PDB:1T2V (Williams et al., 2004) is in blue. Hydrophobic residues in Patch 3 are
labelled as V1654, F1662, M1663 and Y1666.
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position (Lokesh et al., 2007; Yuan et al., 2011a). In order to have the
sidechains of pS (position 0) and F (position þ3) facing to the same
side for BRCT interaction, Pro provides important restraints on the
conformations of peptides towards those adopted when bound to
BRCT domains, so reducing the entropic penalty of peptide binding.
Interestingly, Ramachandran plots for the phosphopeptides in BRCT
tandem-domains-bound conformations show that the phi/psi an-
gles of pSXXF motif residues resemble those of the idealised pol-
yproline II (PPII) helix, which has three residues per turn (Adzhubei
and Sternberg, 1993) (Fig. 3e) and brings sidechains of positions
0 and þ3 to the same side of the helix.
ResiduesGln, Thr andVal are found at theþ2position (Fig. 3c). As
expected foranextendedhelix,mutationof theþ2position fromThr
to Ala reduces the phosphopeptide-binding afﬁnity (Lokesh et al.,
2007). Double mutations of residues þ1 to Asp and þ2 to Glu have
been shown to abolish the phosphopeptide interaction with BRCT
domains (Liu and Ladias, 2013). At positionþ2, the X residue cannot
be large or negatively charged due tounfavourable interactionswith
residue E1698 (Liu and Ladias, 2013).5. Binding outside the motif
The N- and C-terminal sequences of the peptide outside the
motif also contribute towards the peptide interaction. Phospho-
peptides with the same core DpSPVF sequence and peptide length,
but different N-terminal and C-terminal sequences, bind to BRCA1
BRCT domains with dramatically different afﬁnities (Liu and Ladias,
2013). In all structures available so far (as seen in Fig. 2), residues
that are C-terminal to the motif contribute fewer interactions than
the N-terminal residues. When there is no extension of the C-ter-
minal sequence outside the motif, the presence of the þ3 carbox-
ylate terminus is important for binding to BRCT domains through
an additional salt bridge with R1699 (Campbell et al., 2010; Yuan
et al., 2011b). This extra interaction is likely present in another
BRCA1-BRCT-binding protein, Abraxas/CCDC98 (Liu et al., 2007;
Wang et al., 2007), which also has a C-terminal Phe at
Position þ3 in the pSXXF motif.The N-terminal region of the phosphopeptide contains more
hydrophobic interactions with BRCT compared to the C-terminal
sequence (Fig. 2). Surface hydrophobicity of the BRCT domains
using a normalized consensus hydrophobicity scale (Eisenberg
et al., 1984) is shown in Fig. 4. Residue 5 Ile in the Bach1
phosphopeptide of 1T29 structure interacts with hydrophobic
Patch 1, which is formed by V1696, C1697 and V1740 in the loop
region close to the interface between two BRCTs (Shiozaki et al.,
2004). Patch 2, near the beginning of a1 in BRCT1, is formed by
L1657 and P1659. The optimized peptide in structure 1T2V con-
tains a Tyr at 3 position that interacts with P1659, while the
negatively-charged side chain of Asp at the 2 position faces
away from the BRCT domains (Williams et al., 2004). Patch 3
contains F1662, M1663 and Y1666 in a1 and V1654 in b1. This
third hydrophobic patch forms isologous interactions with
another molecule in the crystal for most BRCA1-BRCTs structures
solved so far. It has been shown that having a residue with a
naphthyl side chain at the N-terminal of the motif can increase
peptide binding of the BRCT domains (Lokesh et al., 2007). The
naphthyl interaction is likely mediated through hydrophobic
Patches 2 and 3.
Aside from the sequence differences, phosphorylation variants
in the N-terminal phosphopeptide sequence can also occur. In
addition to the phosphorylation at the Ser residue in pSXXF motif,
an extra Ser residue in the N-terminal region can be phosphory-
lated for Bach1 and Abraxas (Kettenbach et al., 2011; Wang et al.,
2007). The structural and functional consequences of double
phosphorylation are still unknown.6. Conclusion
Initial analyses of phosphopeptide binding to the BRCA1-BRCT
domains focused on the pSXXF motif (Glover et al., 2004; Leung
and Glover, 2011). As more and more proteins are shown to bind
to BRCA1 through the pSXXF motif, the question arises as to how
these proteins compete with each other or are regulated with
respect to binding to BRCA1. The variation of residues outside the
canonical motif and also the residues in the “X positions” of the
Q. Wu et al. / Progress in Biophysics and Molecular Biology 117 (2015) 143e148148motif are clearly keys for control of the binding afﬁnity and
selectivity.
Our current understanding of the similarities and differences of
structural interactions among these phosphopeptides bound to
BRCA1-BRCT domains with respect to afﬁnity underlines the fact
that the phosphopeptides used for binding-afﬁnity assays and
structure determination usually represent only small parts of the
protein structure. It is clear that we need to ask whether the rest of
the phosphoprotein also contributes towards the binding with
BRCA1. Understanding these detailed structures and bindingmodes
of BRCA1 BRCT domains with various phosphopeptides can help us
to understand the function of BRCA1 in various pathways and also
contribute towards knowledge-based design and discovery of
higher afﬁnity BRCA1-BRCT inhibitors in the future.
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